Monopar Therapeutics Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2017 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Monopar Therapeutics quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2017 to Q1 2023.
  • Monopar Therapeutics Share-based Payment Arrangement, Expense for the quarter ending March 31, 2023 was $476K, a 4.72% decline year-over-year.
  • Monopar Therapeutics annual Share-based Payment Arrangement, Expense for 2022 was $1.64M, a 11.8% increase from 2021.
  • Monopar Therapeutics annual Share-based Payment Arrangement, Expense for 2021 was $1.47M, a 11.1% increase from 2020.
  • Monopar Therapeutics annual Share-based Payment Arrangement, Expense for 2020 was $1.32M, a 30.6% increase from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $476K -$23.6K -4.72% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q2 2022 $1.6M $357K -$300 -0.08% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $1.6M $500K +$132K +35.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $1.47M $350K +$18.8K +5.69% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 $1.45M $392K +$108K +38.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $1.34M $358K -$9.77K -2.66% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 $1.35M $368K +$29.7K +8.78% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 $1.32M $331K +$54.5K +19.7% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 $1.27M $284K +$40.8K +16.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $1.23M $367K +$110K +42.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 $1.12M $338K +$105K +44.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
Q4 2019 $1.01M $277K +$43.8K +18.8% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 $967K $243K +$150K +161% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $818K $258K +$169K +191% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 $649K $234K +$119K +104% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
Q4 2018 $529K $233K Oct 1, 2018 Dec 31, 2018 10-Q 2019-11-12
Q3 2018 $93.2K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $88.6K Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-12
Q1 2018 $115K +$115K Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-12
Q1 2017 $0 Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.